Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsViva Health Zoladex Prior Auth Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0151

    Zoladex (goserelin acetate) — Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0151 alerts

    Get alerted when Policy IC-0151 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, dosing limits, indications, and renewal criteria for Zoladex (goserelin acetate) for Viva Health members. Applies to providers requesting coverage for the listed oncologic, gynecologic, fertility preservation, and gender dysphoria indications.

    Policy Summary
    PayerViva Health
    PolicyZoladex (goserelin acetate) — Coverage and Prior Authorization
    Policy CodePolicy IC-0151
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization before initiating Zoladex; initial authorizations are generally valid for 12 months unless a shorter period is specified.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial PA validity
    6 monthsEndometriosis initial
    3 units/84dMax dosing (selected indications)
    1 unit/28dMax dosing (other)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=18 yrsMinimum age
    J9202HCPCS

    Coverage Criteria

    inv-01: Initial Therapy (Section III) — Covered when ALL of the following universal and indication-specific criteria are met

    Covered when ALL of the following universal and indication-specific criteria are met:

    Universal criteria: Member is at least 18 years of age (unless otherwise noted)

    (Section III universal)

    Breast cancer: Member is pre- or peri‑menopausal with hormone receptor‑positive disease and used in combination with adjuvant endocrine therapy, OR used in combination with endocrine therapy for recurrent unresectable or stage IV disease, OR used as palliative treatment for advanced disease; OR member is male (sex assigned at birth) when used in combination with aromatase inhibitor therapy
    Fertility preservation during chemotherapy: Member is premenopausal AND receiving cytotoxic chemotherapy with potential to cause ovarian damage AND has failed or is not a candidate for other fertility preservation methods (e.g., cryopreservation)
    Prostate cancer: Indication per policy for prostate cancer (see dosing and radiotherapy scheduling in dosing section)
    Dysfunctional uterine bleeding (endometrial thinning): Used prior to endometrial ablation
    Endometriosis: Member has not received prior treatment with a GnRH agonist for endometriosis within the prior 6 months
    Ovarian, fallopian tube, or primary peritoneal cancer: Used as a single agent AND member has one of the specified histologies (epithelial ovarian/fallopian tube/primary peritoneal, mucinous neoplasm, clear cell carcinoma, carcinosarcoma, or grade 1 endometrioid carcinoma)
    Head and neck cancer (salivary gland tumors): Member has salivary gland tumors AND used in combination with abiraterone and prednisone AND has androgen‑receptor positive recurrent disease with distant metastases OR unresectable locoregional recurrence with prior radiation OR unresectable second primary with prior radiation
    Uterine sarcoma: Diagnosis of low‑grade stage II–IV endometrial stromal sarcoma or adenosarcoma without sarcomatous overgrowth AND ER/PR positive disease AND member is premenopausal and not suitable for surgery AND used for small tumor volume/indolent growth as additional therapy following total hysterectomy AND used in combination with anastrozole, letrozole, or exemestane
    Gender dysphoria: For members <18: puberty progressed to at least Tanner stage 2; AND diagnosis of gender dysphoria confirmed by a qualified mental health professional or DSM‑5‑TR criteria; AND qualified MHP documents long‑lasting/intense pattern, worsening with puberty, coexisting problems addressed, capacity to consent; AND member informed of effects/side effects and fertility options and has given informed consent (parents/guardians involved for minors); AND for adolescents a pediatric endocrinologist or experienced clinician has confirmed indication and absence of medical contraindications

    inv-33: Initial Therapy rules — Initial authorization durations and dosing limits

    Initial authorization durations and dosing limits

    Initial duration: Initial prior authorization is generally provided for 12 months (365 days) unless otherwise specified; Endometriosis initial validity = 6 months (180 days); Dysfunctional uterine bleeding (endometrial thinning) = valid for 2 doses only (given 4 weeks apart)
    Dosing limits (max units): Prostate cancer, breast cancer, gender dysphoria, and fertility preservation: maximum 3 billable units every 84 days; All other indications: maximum 1 billable unit every 28 days

    HCPCS unit = per 3.6 mg

    inv-34: Dosing / Administration — Dosing options depend on indication

    Dosing options depend on indication:

    Standard dosing for breast cancer, fertility preservation while receiving chemotherapy, and gender dysphoria: Administer 3.6 mg depot every 4 weeks OR 10.8 mg depot every 12 weeks
    Endometriosis and dysfunctional uterine bleeding (endometrial thinning): 3.6 mg only: administer 3.6 mg for 1 or 2 doses 28 days apart; if 1 depot given perform endometrial ablation at 4 weeks; if 2 depots given, perform surgery within 2–4 weeks after second dose

    Endometriosis regimen: 3.6 mg every 28 days for 6 months

    Endometriosis duration: Administer 3.6 mg depot every 28 days for 6 months
    Prostate cancer radiotherapy schedule: Stage B2–C: administer 3.6 mg depot 8 weeks before radiotherapy followed in 28 days by 10.8 mg depot OR four injections of 3.6 mg at 28‑day intervals (two prior to and two during radiotherapy); Palliative advanced prostate cancer: 3.6 mg every 4 weeks OR 10.8 mg every 12 weeks

    inv-02: Renewal Criteria (Section IV) — Authorization may be renewed when ALL of the following are satisfied

    Authorization may be renewed when ALL of the following are satisfied:

    Continuation criteria: Member continues to meet universal and indication‑specific criteria in Section III
    Duration limits: Duration of prior authorization has not been exceeded per Section I (see indication‑specific initial validity)
    Clinical benefit and safety: Absence of unacceptable toxicity from the drug (examples listed) AND for listed cancers (prostate, breast, head and neck, ovarian, uterine sarcoma) demonstrated disease response defined by stabilization or decrease in tumor size or spread

    inv-03: Renewal Criteria — Renewal prior authorization valid when ALL of the following are met

    Renewal prior authorization valid when ALL of the following are met:

    Universal and indication‑specific criteria: Member continues to meet the universal and indication‑specific relevant criteria identified in Section III
    Duration limit: Duration of authorization has not been exceeded (refer to Section I)
    Safety: Absence of unacceptable toxicity from the drug (examples include severe QT/QTc prolongation, severe hyperglycemia/diabetes, cardiovascular events, hypercalcemia, severe injection site/vascular injury, tumor flare, severe hypersensitivity reactions, severe cutaneous adverse reactions including SJS/TEN, DRESS, AGEP, cervical resistance, new or worsening depression)

    inv-04: Disease Response Requirement — For cancer indications

    For cancer indications:

    On‑treatment disease response: For prostate, breast, head and neck (salivary gland), ovarian cancer, or uterine sarcoma: demonstrated disease response defined as stabilization of disease or decrease in tumor size or spread supports renewal

    inv-05: Fertility Preservation Continuation — For fertility preservation

    For fertility preservation:

    Ongoing chemotherapy: Member is still receiving treatment with cytotoxic chemotherapy

    Required for renewal of fertility preservation indication

    inv-06: Gender Dysphoria Continuation — For gender dysphoria

    For gender dysphoria:

    Clinical benefit monitoring: Member has shown a beneficial response to treatment as evidenced by routine monitoring of clinical pubertal development (if applicable) and applicable laboratory parameters

    Supports renewal for gender dysphoria indications

    Documentation and specialist confirmation: Diagnosis confirmed by a qualified mental health professional and (for adolescents) a pediatric endocrinologist or clinician experienced in pubertal assessment has confirmed indication and absence of medical contraindications; informed consent documented

    Documentation per policy requirements

    inv-07: Diagnosis-based coverage — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Diagnosis requirement: Member has a diagnosis that matches one of the ICD‑10 codes listed in Appendix 1 (see Appendix 1, chunks 36–48)

    Appendix 1 contains the exhaustive list of supported ICD‑10 codes for zoladex coverage

    For the endometriosis indication, prior authorization will be denied when the member has received treatment with a GnRH agonist within the prior 6 months. This exclusion applies specifically to prior use of a GnRH agonist for the same endometriosis indication and is intended to prevent repeat courses within a 6-month window.

    Authorizations may not be renewed if the member experiences unacceptable toxicity

    The policy’s Appendix 1 lists ICD-10 codes used to support coverage determinations for goserelin. Note that codes F64.0 and F64.9 are referenced in the appendix but are documented as discontinued effective 10/1/26; the policy also shows F64.A becoming effective 10/1/26. Providers and billing staff must ensure submitted diagnosis codes reflect the current ICD-10 lifecycle when requesting authorization or submitting claims.

    Coding and Billing

    HCPCS CodesHCPCSCovered
    J9202Goserelin acetate implant, per 3.6 mg; 1 billable unit = 3.6 mg
    NDC CodesNDCCovered
    70720-0951-XXZoladex 10.8mg 3-Month Implant
    70720-0950-XXZoladex 3.6mg Implant
    Covered ICD-10 CodesICD-10Covered
    C06.9Malignant neoplasm of mouth, unspecified
    C07Malignant neoplasm of parotid gland
    C08.0Malignant neoplasm of submandibular gland
    C08.1Malignant neoplasm of sublingual gland
    C08.9Malignant neoplasm of major salivary gland, unspecified
    C48.1Malignant neoplasm of specified parts of peritoneum
    C48.8Malignant neoplasm of peritoneum, unspecified
    C50.011Malignant neoplasm of nipple and areola, right female breast
    C50.012Malignant neoplasm of nipple and areola, left female breast
    C50.019Malignant neoplasm of nipple and areola, unspecified female breast
    1–10 of 113
    1/12
    Covered ICD-10 Diagnosis CodesICD-10Covered
    C57.3Malignant neoplasm of left round ligament = Malignant neoplasm of parametrium
    C57.4Malignant neoplasm of uterine adnexa, unspecified
    C57.7Malignant neoplasm of other specified female genital organs
    C57.8Malignant neoplasm of overlapping sites of female genital organs
    C57.9Malignant neoplasm of female genital organ, unspecified
    C61Malignant neoplasm of prostate
    D37.031Neoplasm of uncertain behavior of the sublingual salivary glands
    D37.032Neoplasm of uncertain behavior of the submandibular salivary glands
    D37.039Neoplasm of uncertain behavior of the major salivary glands, unspecified
    F64.0Transsexualism (note: listed but discontinued effective 10/1/26)
    1–10 of 157
    1/16
    Dosage intervals — Zoladex (goserelin acetate)
    Standard dosing intervals3.6 mg depot every 4 weeks OR 10.8 mg depot every 12 weeks (standard schedules for breast cancer, fertility preservation during chemotherapy, and gender dysphoria)
    Endometriosis / dysfunctional uterine bleeding3.6 mg depot only: single or two doses given 28 days apart; endometrial ablation timing specified after 1 or 2 depots
    Ovarian cancer / salivary gland tumors / uterine sarcoma3.6 mg depot every 4 weeks (indication-specific schedule)
    Prostate cancer radiotherapy scheduleStage B2-C: 3.6 mg depot 8 weeks before radiotherapy then 10.8 mg depot 28 days later OR four 3.6 mg depots at 28-day intervals; palliative advanced disease: 3.6 mg every 4 weeks OR 10.8 mg every 12 weeks
    ICD-10 effective change date

    Provider Actions and Documentation

    Prior Authorization

    Prior authorization validity and age requirement

    Prior authorization is required. Initial prior authorization will be provided for 12 months (365 days) unless otherwise specified; endometriosis initial validity is 6 months (180 days) and dysfunctional uterine bleeding is limited to 2 doses given 4 weeks apart. Members must be at least 18 years of age unless otherwise noted.

    • Initial: 12 months (365 days) unless otherwise specified.
    • Endometriosis: initial validity 6 months (180 days).
    • Dysfunctional uterine bleeding: provided for 2 doses only (given 4 weeks apart).
    • Member generally must be ≥18 years old unless otherwise noted.
    Step Therapy

    Renewal requirements

    Prior authorization may be renewed when the member continues to meet the universal and indication‑specific criteria, the duration of authorization has not been exceeded, and there is absence of unacceptable toxicity.

    Continuation and Renewal Criteria

    inv-35: Continuation Therapy — Renewal/continuation requirements

    Renewal/continuation requirements

    Continuation: Member continues to meet initial criteria, duration not exceeded, absence of unacceptable toxicity, and for certain cancers demonstrated disease response (stabilization or decrease in tumor burden)

    inv-36: Continuation / Renewal — Criteria to renew authorization/continue therapy vary by indication

    Criteria to renew authorization/continue therapy vary by indication:

    General renewal: Continue when universal and indication‑specific criteria are met, duration not exceeded, and no unacceptable toxicity
    Cancer response: For prostate, breast, head and neck (salivary gland), ovarian cancer, or uterine sarcoma: evidence of disease stabilization or tumor decrease supports continuation/renewal

    Step Therapy and Prioritization

    StepRequirementCoverage status
    1Member is premenopausal AND receiving cytotoxic chemotherapy with potential to cause ovarian damage AND has failed or is not a candidate for other fertility preservation methods (e.g., cryopreservation)Covered when criteria met
    StepNQTL RationaleAction
    1Prior authorization applied due to cost of drug as identified in the NQTL factor checklist (Cost of drug: Yes — consider for PA)Prior authorization required

    Quantity Limits

    Quantity limit — Zoladex (3 units/84 days)
    DrugZoladex (goserelin acetate) — applies to prostate cancer, breast cancer, gender dysphoria, and fertility preservation indications
    Quantity limit3 billable units (max) per 84 days
    ScopeLimit applies to specified indications: Prostate Cancer, Breast Cancer, Gender Dysphoria, and Fertility Preservation
    Quantity limit — Zoladex (1 unit/28 days)
    DrugZoladex (goserelin acetate) — applies to all other indications not specified in the 3-unit/84-day group
    Quantity limit1 billable unit (max) per 28 days
    Scope

    Background

    Goserelin (Zoladex) is a gonadotropin-releasing hormone (GnRH) agonist used to suppress gonadal steroid production across multiple indications including oncologic and gynecologic conditions, fertility preservation during cytotoxic chemotherapy, and pubertal suppression/suppression of sex hormones in gender dysphoria management. The policy details approved uses, dosing schedules, diagnostic code requirements, and renewal criteria to guide prior authorization and clinical management.

    Definitions

    Qualified mental health professional — minimum qualifications
    DefinitionQualified mental health professional: licensed by statutory body and holding at minimum a master's degree or equivalent training in a clinical field relevant to this role
    Diagnostic competencyMust be competent using the latest ICD (where required) or equivalent taxonomy for diagnosis
    Clinical skillsAble to identify co-existing mental health or psychosocial concerns and distinguish these from gender dysphoria; assess capacity to consent; experienced/qualified to assess clinical aspects of gender dysphoria
    Professional developmentUndergo continuing education in health care relating to gender dysphoria, incongruence, and diversity
    Disease response — renewal requirement for cancer indications
    Definition
    Policy Summary
    PayerViva Health
    PolicyZoladex (goserelin acetate) — Coverage and Prior Authorization
    Policy CodePolicy IC-0151
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization before initiating Zoladex; initial authorizations are generally valid for 12 months unless a shorter period is specified.
    SourceLink
    On This Page
    Coverage CriteriaCoding and BillingProvider Actions and DocumentationContinuation and Renewal CriteriaStep Therapy and PrioritizationQuantity LimitsBackgroundDefinitions
    Code discontinuedICD-10 F64.9 (Gender identity disorder, unspecified) — noted as discontinued effective 10/1/26
    New/updated code effectiveICD-10 F64.A (Gender identity disorder, in remission) — effective 10/1/26
    Policy coding noteAppendix 1 lists F64.A and notes F64.9 discontinuation; coverage should reflect code lifecycle
    • Renewal generally may be granted every 12 months (365 days) unless otherwise specified.
    • Endometriosis and dysfunctional uterine bleeding: prior authorization may NOT be renewed.
    • Fertility preservation while receiving chemotherapy: may be renewed every 12 months while member remains on cytotoxic chemotherapy.
    Prior Authorization

    Diagnosis required from Appendix 1

    Submit a supported diagnosis code from Appendix 1 with the authorization request; coverage requires the member have a diagnosis that matches one of the ICD‑10 codes listed in Appendix 1.

    • Appendix 1 contains the exhaustive list of supported ICD‑10 codes for zoladex coverage.
    • Claims should include one of the listed covered diagnosis codes to support medical necessity.
    Prior Authorization

    Fertility preservation during chemotherapy

    For fertility preservation during cytotoxic chemotherapy, Zoladex is authorized when the member is premenopausal, is receiving cytotoxic chemotherapy with potential to cause ovarian damage, and has failed or is not a candidate for other fertility preservation methods.

    • Member must be premenopausal.
    • Member must be receiving cytotoxic chemotherapy with potential ovarian toxicity (examples provided in policy).
    • Member has failed or is not a candidate for other fertility preservation methods (e.g., cryopreservation).
    Note

    Prior authorization applied due to cost (NQTL)

    Prior authorization is applied in part because of drug cost considerations as identified in the policy's NQTL factor checklist.

    • Appendix A NQTL checklist: 'Cost of drug' was identified as a factor to consider for prior authorization.
    Note
    Documentation Required

    Documentation required for gender dysphoria

    For gender dysphoria indications, documentation must include diagnosis confirmation by a qualified mental health professional and records that the qualified MHP (and for adolescents, a pediatric endocrinologist or clinician experienced in pubertal assessment) have confirmed required assessment criteria and absence of medical contraindications.

    • Diagnosis of gender dysphoria must be confirmed by a qualified MHP or meet DSM‑5‑TR criteria.
    • Qualified MHP must confirm long‑lasting/intense pattern, worsening with puberty, coexisting problems addressed, and capacity to consent.
    • For adolescents, pediatric endocrinologist or experienced clinician must confirm agreement in indication and no medical contraindications.
    Documentation Required

    Documentation required for renewal

    Renewal documentation must support that the member continues to meet the universal and indication‑specific criteria, include dates showing the duration of authorization has not been exceeded, and demonstrate absence of unacceptable toxicity.

    • Provide evidence that universal and indication‑specific criteria remain met.
    • Include dates to show duration limits (refer to Section I) have not been exceeded.
    • Document absence of unacceptable toxicities listed in the policy.
    Billing Rule

    Include covered diagnosis code on claim

    Claims and authorization requests should include one of the covered ICD‑10 diagnosis codes from Appendix 1 to support medical necessity.

    • Appendix 1 lists the ICD‑10 codes that qualify for coverage (see policy Appendix 1).
    Denial Risk

    Unacceptable toxicity can trigger denial

    The presence of unacceptable toxicity may lead to denial or non‑renewal; examples of unacceptable toxicities include severe QT/QTc prolongation, severe hyperglycemia/diabetes, cardiovascular events (e.g., myocardial infarction, stroke), hypercalcemia, severe injection site/vascular injury, tumor flare, severe hypersensitivity reactions, severe cutaneous adverse reactions (SJS/TEN, DRESS, AGEP), cervical resistance, and new or worsening depression.

    • Document and assess for listed severe toxicities prior to renewal.
    • If unacceptable toxicity is present, renewal may be denied.
    Denial Risk

    Renewal denial triggers

    Renewal may be denied if the member no longer meets the universal or indication‑specific criteria, the authorization duration has been exceeded, or unacceptable toxicity from the drug is present.

    • Verify continued fulfillment of Section III criteria before requesting renewal.
    • Confirm authorization duration has not been exceeded (see Section I).
    Note

    Medicare coverage dependency (follow CMS NCD/LCD/LCA)

    For Medicare members, coverage determinations for outpatient drugs are subject to the Medicare Benefit Policy Manual and applicable NCDs, LCDs, and LCAs; compliance with those CMS determinations is required where applicable and noncompliance may affect coverage.

    • Use CMS NCD/LCD/LCA guidance where applicable for Medicare Part B coverage decisions.
    • Search the Medicare Coverage Database for relevant NCDs/LCDs/LCAs as noted in Appendix 2.
    Fertility preservation: Member is still receiving cytotoxic chemotherapy
    Gender dysphoria: Member has shown beneficial response evidenced by routine pubertal and laboratory monitoring where applicable
    Applies to all other indications (e.g., indications outside prostate, breast, gender dysphoria, fertility preservation)
    Disease response (cancer indications): stabilization of disease or decrease in size of tumor or tumor spread
    PurposeRequired evidence to support renewal for prostate, breast, head and neck, ovarian cancer, or uterine sarcoma indications
    ApplicationDemonstrated disease response supports continued authorization under renewal criteria
    Medicare Part B guidance and contractor coverage references
    Medicare Part B referenceMedicare Benefit Policy Manual (Pub. 100-02), Chapter 15, §50 governs outpatient (Part B) drugs
    NCDs/LCDs/LCAsNational Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may apply and must be followed where relevant
    Search resourceCMS Medicare Coverage Database: https://www.cms.gov/medicare-coverage-database/search.aspx (for NCD/LCD/LCA lookup)